Integra LifeSciences IART Specialty Surgery — Intangible asset amortization

Other segment segments

Tissue Reconstruction

$0—

Similar metrics at other companies

KMPRSpecialty Property & Casualty Insurance — Intangible Amortization

$4.7M+11.9%

NOVTMedical Solutions — Intangible Amortization

$3.66M+16.2%

ASBCorporate and Commercial Specialty — Intangible Amortization

$0—

PRMSpecialty Products — Depreciation and amortization expense

$12.65M+206%

COLLSegment — Intangible asset amortization

$55.47M0.0%

GTLSSpecialty Products — Amortization expense

$4.4M-12.0%

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B-56.8%

Enterprise value$3.12B-26.7%

P/S0.8×-1.1×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's specialty surgery — intangible asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's specialty surgery — intangible asset amortization?: Integra LifeSciences (IART) reported specialty surgery — intangible asset amortization of $0 in Q1 2026.
What does specialty surgery — intangible asset amortization mean?: This metric reflects the periodic expense recognized for the systematic allocation of the cost of intangible assets, such as patents and acquired technology, within the Specialty Surgery segment. It provides insight into the non-cash costs associated with maintaining the segment's intellectual property portfolio.